Track market-moving stories before they get noisy

On October 22, 2026, Medtronic PLC MDT shares rose 3.8% to a current price of $96.59. This movement comes amid a 52-week range of $73.31 to $106.33, indicating a strong upward trend recently.

GF Value™ verdict: Current price is $96.59, compared to GF Value™ of $101.17, indicating the stock is 4.5% undervalued.GF Score™ is 82/100, suggesting strong overall performance by the company.Notable signal: Insider activity shows $14.7 million in sales over the past 12 months, with no buying reported.Is MDT Overvalued or Undervalued?Medtronic PLC's current share price of $96.59 is 4.5% below the GF Value™ estimate of $101.17, indicating that the stock may be undervalued. This margin of safety can present a potential opportunity for investors looking for growth in the medical devices sector. The GF Valuation label classifies MDT as fairly valued, suggesting that the market has priced the stock reasonably in relation to its intrinsic value according to GuruFocus' analysis. The GF Value™ is derived from historical trading multiples, past business growth, and future performance estimates, reflecting a comprehensive view of the company’s valuation.

While the stock appears undervalued, it is essential to consider the risks associated with this assessment, particularly in light of the insider selling activity, which could indicate a lack of confidence from those closest to the company. Thus, while there is an opportunity, prospective investors should remain cautious.

How Does MDT's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)23.8x26.5xForward P/E16.2xN/ACurrently, Medtronic's P/E ratio of 23.8x is below its 5-year median P/E of 26.5x, suggesting that the stock is trading at a discount compared to its historical valuation. This aligns with the GF Value™ verdict of being undervalued, reinforcing the idea that the stock may present a buying opportunity for long-term investors.

What Does MDT's GF Score™ Tell Us?The GF Score™ is a comprehensive measure that evaluates a company's financial health and growth potential by analyzing various factors. Medtronic's GF Score™ of 82/100 reflects strong performance, with notable strengths in profitability and valuation.

MetricRatingGF Score™82Financial Strength6/10Profitability8/10Growth5/10Valuation9/10Momentum8/10Medtronic stands out particularly in its valuation rank of 9/10, indicating a strong relative pricing compared to peers, and its profitability rank of 8/10 suggests robust earnings. However, the financial strength score of 6/10 indicates that there might be some areas of concern regarding its balance sheet. Overall, the scores reflect a company that is well-positioned in terms of valuation and profitability, yet with some caution warranted regarding financial robustness.

What Are Gurus and Insiders Doing with MDT?Currently, 20 gurus hold shares of Medtronic, with 14 increasing their positions and 6 reducing their holdings in recent quarters. This positive guru activity suggests a degree of confidence in the company's prospects among experienced investors. However, insider activity reveals that insiders have sold $14.7 million worth of shares over the past 12 months without any reported buying, which may raise some red flags regarding internal sentiment about the company’s future.

This pattern of insider selling, contrasted with the buying trend from gurus, could imply a divergence in confidence levels. While gurus are still optimistic about the stock, insiders may be taking profits, indicating a need for potential investors to weigh this information carefully before making decisions.

What This Means for InvestorsBased on the GF Value™ assessment, Medtronic PLC MDT is currently undervalued, presenting a potential opportunity for investors who are looking for attractive entry points in a solid medical devices company. However, the insider selling activity should not be overlooked, as it may suggest caution. Overall, investors are encouraged to stay informed and consider all aspects of the company’s performance and market signals.

For more detailed insights, you can visit the Medtronic PLC MDT stock page and explore the GF Value™ page for further analysis.

Frequently Asked QuestionsWhat is MDT's GF Score™?

Medtronic has a GF Score™ of 82/100, indicating strong overall performance with a solid valuation and profitability metrics.

Is MDT overvalued or undervalued?

MDT is currently undervalued, with a GF Value™ of $101.17 compared to its current price of $96.59, suggesting a 4.5% upside.

What is MDT's P/E ratio?

MDT's P/E ratio is 23.8x, which is below its 5-year median of 26.5x, indicating that the stock is trading at a discount to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias
Medtronic continues to strengthen its position in cardiac ablation, building on a legacy of innovation in electrophysiology

, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive real-world registry results for the Affera™ Mapping and Ablation System with the Sphere-9™ Catheter and the PulseSelect™ Pulsed Field Ablation (PFA) System. The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia (VT).

"These favorable results reinforce our confidence in the safety and performance of our ablation technologies worldwide. It is very encouraging to see physicians' positive response and real-world evidence that supports effective, safe, and efficient care for patients with a wide range of arrhythmias," said Khaldoun Tarakji, M.D., MPH, Vice President and Chief of Science, Research and Technology, Electrophysiology Therapies at Medtronic.

APEX registry: Sphere-9 real-world outcomes in atrial fibrillation
The APEX global prospective registry analysis included 1,050 patients with AFib treated with the Sphere-9 catheter and Affera Mapping and Ablation System across 28 global sites. The major complication rate was low at 1.1%, with no acute kidney injury, severe coronary spasm or phrenic nerve injury. Major complication rates did not differ significantly between de novo and repeat ablation procedures.

REAL PULSE global registry: PulseSelect real-world safety and performance
The REAL PULSE global prospective registry analysis included 1,160 atrial fibrillation patients treated with the PulseSelect PFA system across 38 global sites. Results were positive, including a 100% acute success rate and a low acute major complication rate of 0.09%.

APEX registry: Expanding evidence in ventricular tachycardia
A separate European APEX registry analysis evaluated use of the Sphere-9 catheter in patients undergoing ablation for VT, demonstrating promising results for the potential of the Sphere-9 catheter and pulsed field ablation in a patient population that can be challenging to treat.

The analysis included 46 patients with ischemic and non-ischemic sustained VT and demonstrated high acute success (87%) and estimated six-month freedom from VT recurrence (75%).
There was no significant difference in long-term freedom from arrhythmia recurrence in ischemic and non-ischemic cardiomyopathy patients.
Six major complications were reported in four patients.

Sphere-9 is CE marked for VT and is investigational only and not approved for VT in the United States. The ventricular ablation indication may not be approved or cleared in all markets.

"As momentum continues to build across our portfolio, it is encouraging to see long-term data support the safety and efficacy profiles of our ablation technologies and the positive impact they are having on procedural workflows," said Felicia Kurz, Vice President and General Manager, Cardiac Ablation Solutions, which is part of the Electrophysiology Therapies business at Medtronic. "We will continue to innovate and strengthen our leadership in cardiac ablation, with a focus on advancing safe, effective and efficient care for patients."

The Medtronic cardiac ablation portfolio offers physicians multiple technologies for patient care, including the Sphere-9 catheter, an all-in-one catheter that combines high-definition mapping with pulsed field and radiofrequency ablation using the Affera mapping and ablation system, and the PulseSelect PFA system, a single-shot solution for pulmonary vein isolation.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit Medtronic.com and follow @Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Leslie Williamson
Public Relations
+1-612-227-5099

Ingrid Goldberg
 Investor Relations
+1-763-505-2696

SOURCE Medtronic plc

Medtronic (MDT - Free Report) ended the recent trading session at $92.77, demonstrating a -2.09% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.41% for the day. On the other hand, the Dow registered a loss of 0.07%, and the technology-centric Nasdaq increased by 1.11%.

Heading into today, shares of the medical device company had gained 2.84% over the past month, outpacing the Medical sector's gain of 1.97% and the S&P 500's gain of 1.46%.

Market participants will be closely following the financial results of Medtronic in its upcoming release. In that report, analysts expect Medtronic to post earnings of $1.34 per share. This would mark a year-over-year decline of 1.47%. Our most recent consensus estimate is calling for quarterly revenue of $9.47 billion, up 5.66% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.98 per share and revenue of $38.97 billion, indicating changes of +8.14% and +7.16%, respectively, compared to the previous year.

Investors might also notice recent changes to analyst estimates for Medtronic. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.15% rise in the Zacks Consensus EPS estimate. Medtronic is currently sporting a Zacks Rank of #3 (Hold).

From a valuation perspective, Medtronic is currently exchanging hands at a Forward P/E ratio of 15.85. For comparison, its industry has an average Forward P/E of 20.56, which means Medtronic is trading at a discount to the group.

Also, we should mention that MDT has a PEG ratio of 2.16. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MDT's industry had an average PEG ratio of 1.89 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 96, this industry ranks in the top 40% of all industries, numbering over 250.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

The money isn’t chasing one drug. It’s following a shift in where artificial intelligence (AI) is pointed. Chips, code and business data defined the first waves of the AI trade. The next target is the human body, a data set with 8 billion members.

That shift puts some of medicine’s biggest challenges—cancer, heart disease, dementia and aging—squarely in focus. These conditions affect billions of lives, and AI is giving researchers new ways to understand their underlying biology, turning once-daunting medical mysteries into problems that can increasingly be modeled, tested and addressed with greater precision.

Get Eli Lilly and Company alerts:

AI Is Turning the Medical Race Into an Engineering RaceThe framework comes from Keith Kaplan, CEO of TradeSmith, who calls this wave biointelligence. Earlier AI waves read chips, code and business data. This one reads people, a market that never runs out of customers.

Wall Street has started pricing that in. Eli Lilly and Company NYSE: LLY briefly touched a $1 trillion valuation last November, a first for a healthcare company. In August, Moderna NASDAQ: MRNA and partner Merck & Co. NYSE: MRK reported that their personalized cancer vaccine met its primary and key secondary endpoints in a Phase 3 melanoma trial, the first late-stage win ever for an mRNA cancer therapy.

Two trends collided to make that possible. Sequencing a human genome fell from about $100 million in 2001 to a few hundred dollars, and AI became exceptionally good at finding patterns in oceans of data. Kaplan splits the opportunity into three moves: read the body, rewrite it, and replace what can’t be saved.

Reading, Rewriting and Replacing the Body Have Reached the ClinicReading already has a face. Ann Johnson lost her speech to a brainstem stroke at 30. Eighteen years later, a UC San Francisco team used AI to decode her brain signals into speech, placing 253 electrodes on the surface of her brain and translating her attempts to speak into words at about 80 per minute, against 14 on her previous device. The electrodes weren’t new—the AI that could interpret them was.

Rewriting looks like Moderna’s personalized cancer vaccine, which uses AI to analyze mutations in a melanoma patient’s tumor and identify up to 34 targets for the patient’s immune system to attack. Replacing is further out, with gene-edited pig organs aimed at a transplant list of roughly 100,000 Americans.

Platforms That Compound Beat Biotech Lottery TicketsHere’s where it gets frustrating for investors. The purest brain-interface plays, including Neuralink, Synchron and Paradromics, are private, and the closest public door is Medtronic NYSE: MDT.

That pushes the public trade toward data, platforms and distribution. The old biotech model was pick the right molecule or lose everything. Now every test Guardant Health NASDAQ: GH runs sharpens the next, and every patient in the Tempus AI NASDAQ: TEM library improves the next answer. These businesses compound.

In Kaplan’s framing, the group is a decade-long menu, not a checklist. Start with profitable large caps and toll-booth names, size speculative positions small and expect biotech-style swings. He sorts 12 biointelligence stocks into four risk groups in a free report, which is where the four names below come from.

Blood Tests and Sequencers Get Paid on Every BreakthroughGuardant Health Today

GH

Guardant Health

$156.38 -2.22 (-1.40%)

As of 10:53 AM Eastern

This is a fair market value price provided by Massive. Learn more.

$65.96▼

$191.05$190.00

Guardant Health’s Shield test screens for colorectal cancer, the second-deadliest cancer in the United States, from an ordinary blood draw. About a third of eligible adults skip screening rather than face a colonoscopy, and a blood test changes that math.

Adoption is moving fast. Second-quarter screening revenue reached $52.9 million against $14.8 million a year earlier, on roughly 66,000 Shield tests versus 16,000. The test has entered American Cancer Society guidelines, UnitedHealth Group NYSE: UNH now covers it, and about 70 million lives have access to it.

Kaplan expects a strong report in late October, since early detection costs insurers far less than late-stage treatment.

Illumina Today

$262.42 -0.12 (-0.05%)

As of 10:53 AM Eastern

This is a fair market value price provided by Massive. Learn more.

$94.00▼

$309.3548.90

$231.88

Illumina NASDAQ: ILMN sells the shovels in this gold rush. It builds the sequencers behind collapsing genome costs, then sells the reagent kits those machines consume for years.

Three lost years on a botched acquisition are behind it; guidance moved up to a range of $4.60 billion to $4.64 billion, and the stock rejoined the S&P 500 in September. Kaplan’s view is that Illumina benefits from every trial that starts with a sequence, which makes sequencing volume the number to watch.

Pharma Scale and a Cash-Burning Cancer Bet Set the Risk RangeEli Lilly and Company Today

LLY

Eli Lilly and Company

$1,246.10 -10.93 (-0.87%)

As of 10:53 AM Eastern

This is a fair market value price provided by Massive. Learn more.

$793.82▼

$1,292.650.56%

41.78

$1,313.43

Eli Lilly anchors the steadier end. Revenue hit $65 billion last year, up 45%, and guidance calls for $85 billion to $87 billion this year. Beyond Mounjaro, an oral GLP-1 pill won approval in April, and retatrutide, an experimental triple agonist, delivered average weight loss of 71 pounds in Phase 3, with a filing targeted for early 2027.

The bigger story may sit outside weight loss. Lilly runs 42 Phase 3 programs, with about three-quarters of its new medicines outside GLP-1s, and committed up to $2.75 billion in March for exclusive rights to an AI drug discovery platform.

Moderna Today

$225.45 +7.44 (+3.41%)

As of 10:53 AM Eastern

This is a fair market value price provided by Massive. Learn more.

$22.28▼

$242.29$101.45

Moderna sits at the other extreme. Nine trials with Merck span melanoma, lung, bladder, and kidney cancer, and the AI that picks targets for each patient is the product. The catch is a quarterly loss of roughly $800 million.

Nasdaq-100 inclusion took effect in October, which forces index-tracking funds to buy, and full Phase 3 data is expected later this month with earnings right behind it.

Waiting until after earnings may be sensible, per Kaplan, who sizes the stock as speculative.

Data Engines, Not Single Molecules, Connect This Biotech BasketPull the thread through all four, and the link is information. Guardant Health reads it from blood, Illumina sequences it, Eli Lilly turns it into medicines at a global scale, and Moderna rewrites it into personalized vaccines. Each gets sharper as data piles up, which separates this group from old binary bets on a single trial.

The upside is a decade of compounding across testing, tools and therapy. The risk is valuation after big runs, Moderna’s losses and the volatility that has always shadowed biotech, and none of it pays off without adoption by insurers, regulators and labs.

Stay focused on adoption and data volume, because that’s what moves biointelligence stocks from science headlines into earnings.

Should You Invest $1,000 in Eli Lilly and Company Right Now?Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Medtronic (MDT -0.73%) has raised its quarterly dividend for 49 consecutive years. This means the medical device and technology company is just one year away from earning Dividend King status, which is reserved for stocks with at least 50 years of consecutive annual dividend growth.

Last June, Medtronic raised its quarterly dividend to $0.72 per share, yielding an annualized dividend of $2.88 per share. With this in mind, how many shares would you need to own to generate $1,000 per year in annual dividend income?

Image source: Getty Images.

Medtronic and the math behind $1,000 in dividend income
Based on the annualized dividend of $2.88 per share, an investor would need to own roughly 348 shares of Medtronic. This position would generate $1,002.24 in annual dividend income. Based on Medtronic's current stock price, you would need about $32,792 to buy those 348 shares. Investing in Medtronic shares right now would yield around 3% annually.

MDT Medtronic$94.75-$0.70 (-0.73%)

NYSE · As of 4:00 PM ET 10/16/26

Although Medtronic's dividend increases lately have been modest, with a 1.4% increase this year and an average 2% increase over the past three years, there is potential for larger dividend increases in the years ahead.

MiniMed spinoff could change the growth story
Last March, Medtronic took MiniMed Group (MMED -2.83%), its lower-margin diabetes business, public. Just this week, the company completed its spinoff of MiniMed, via an exchange offer.

Post-spinoff, Medtronic can now focus more on its higher-margin cardiovascular, neuroscience, and surgical businesses. Moreover, with MiniMed trading at a higher earnings multiple, the spinoff points to steady earnings growth. Analyst estimates call for earnings growth of 8.1% and 7.1%, respectively, during the fiscal years ending January 2027 and January 2028.

With its forward payout ratio already at a reasonable 48%, upper-single-digit earnings growth could pave the way for larger dividend increases than in the recent past. Alongside the prospect of improved dividend growth, investors could also reward Medtronic, trading at the midrange of valuations among medical device stocks, with a higher valuation.

Annual list recognizes inventions making the world better and smarter

, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Stealth AXiS™ surgical system and the Corsano™* multi-parameter wearable have been named to the TIME Best Inventions of 2026 list.

The annual award highlights the most impactful new products and ideas of the year, assessed by TIME editors. The dual recognition highlights the Medtronic enterprise-wide commitment to transforming healthcare through connected technologies that help clinicians make more informed decisions and improve care delivery.

Advancing connected surgery with Stealth AXiS™
The Stealth AXiS™ surgical system was recognized for bringing planning, navigation, and robotic-assisted execution together in a single platform designed for complex procedures. The system addresses challenges in surgery, where technologies for planning, imaging, navigation, and execution are often fragmented across multiple systems.

Built within Medtronic's AiBLE™ smart ecosystem, the Stealth AXiS™ system supports spinal, cranial, and ear, nose, and throat (ENT) procedures by integrating real-time data, advanced imaging, and AI-based capabilities into the surgical workflow to create a more connected approach to care across the surgical journey.

"Being named a TIME Best Invention is meaningful recognition of the innovation behind the Stealth AXiS™ system and our commitment to advancing the connected surgical ecosystem," said Michael Carter, president of the Cranial and Spinal Technologies operating unit within the Neuroscience Portfolio at Medtronic. "Our goal is to help surgical teams work with greater connectivity and intelligence by bringing planning, navigation, and robotics together in one integrated platform."

Expanding continuous patient monitoring with Corsano™* multi-parameter wearable
The Corsano™* multi-parameter wearable was recognized for its ability to extend clinical visibility beyond traditional bedside monitoring through a lightweight, tetherless wearable designed to capture key vital parameters and trending information to inform clinical decision making. Manufactured by Corsano Health B.V. and distributed in the U.S. and Western Europe by Medtronic, the wearable provides clinicians access to patient data in near real time, from the hospital to the home setting.

While spot checking alone can leave patients unmonitored 96% of the time1, the medical-grade wearable monitors pulse rate, blood oxygen saturation (SpO₂), respiration rate, skin temperature, and activity, helping clinicians access timely patient information while enabling patient mobility and comfort.

"This recognition on the TIME Best Inventions list is a testament to what's made possible by the next generation of patient monitoring," said Kate Benedict, president of the Acute Care & Monitoring operating unit within the Medical Surgical Portfolio at Medtronic. "The Corsano™* multi-parameter wearable meaningfully expands our portfolio of wearable patient monitoring solutions and reflects our commitment to helping clinicians stay connected to patient data wherever care is delivered, enabling more informed decisions with patient insights."

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and pursue better outcomes, before, during, and beyond surgery.

About Acute Care & Monitoring
At Medtronic Acute Care & Monitoring, we put patients first by designing patient monitoring and airway management technologies that support care in the moments that matter. By simplifying clinical decision making, workflows, and operational performance, we help care teams stay focused on patients while helping organizations create sustainable value from their technology investments. We do this to support our vision: to enable personalized patient care, anytime, anywhere. For more information, visit medtronic.com/ACM.

About the Ear, Nose, & Throat Business at Medtronic
Medtronic's Ear, Nose, and Throat (ENT) business is the global market leader in ENT, delivering innovative technologies that impact nearly 3 million patients each year. For more than 25 years, we have collaborated with physicians to advance care across the specialty. Our portfolio supports surgical procedures related to chronic rhinosinusitis and head and neck cancers, spanning surgical navigation, tissue health, powered instruments, localized drug delivery, intraoperative nerve monitoring, and parathyroid detection. As the global leader in ENT navigation since the introduction of the LandmarX™ image-guided surgery system in 1998, we continue to advance the field with next-generation platforms including the Stealth AXiS™ Surgical System. For more information, visit Medtronic.com/AXiSENT.

About Corsano Health 
Corsano Health B.V. is a leading MedTech company that creates, manufactures, and sells advanced real-time remote patient monitoring solutions. With a CE-MDR medically certified system and FDA clearance, the Corsano™ multi-parameter wearable is setting new standards for continuous monitoring, focusing on our mission to lower healthcare costs and support clinical teams in improving outcomes and patient experiences. For more information, visit https://corsano.com/.

*The Corsano™* multi-parameter wearable is manufactured by Corsano Health B. V. and distributed by Medtronic. The Corsano™ multi-parameter wearable should not be used as the sole basis for diagnosis or therapy and is intended only as an adjunct in patient assessment. It is not intended for use in high-acuity environments or on acutely ill cardiac patients with potential to develop life-threatening arrhythmias, or for SpO2 monitoring in conditions of high motion or low perfusion.

1Curry and Jungquist: A critical assessment of monitoring practices, patient deterioration, and alarm fatigue on inpatient wards: a review. Patient Safety in Surgery 2014 8:29.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Justin Paquette

Ingrid Goldberg

Public Relations

Investor Relations

+1-612-271-7935

+1-763-505-2696

SOURCE Medtronic plc

, /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc ("Medtronic"; NYSE: MDT), marking its first day as a fully independent company.

"Today marks the completion of our separation from Medtronic and a significant milestone for MiniMed," said Que Dallara, Chief Executive Officer of MiniMed. "We are grateful to Medtronic for its partnership and support in reaching this point. As an independent company, we have the freedom to make the decisions we believe are right for our business and the people we serve, and the responsibility to see those decisions through. Our focus now is to put that independence to work and continue advancing what is possible in diabetes care."

As separately announced yesterday, Medtronic accepted an aggregate of 55,032,401 Medtronic ordinary shares in exchange for 252,813,348 shares of MiniMed common stock. As a result, Medtronic no longer holds an equity stake in MiniMed. The exchange offer was 5.4x subscribed.

Full details of the results of the exchange offer are available in a separate press release issued yesterday by Medtronic. The exchange agent will promptly credit newly issued shares of MiniMed common stock in book-entry form to accounts maintained by the MiniMed transfer agent for tendering shareholders whose Medtronic ordinary shares were accepted in the exchange offer. Checks in lieu of fractional shares of MiniMed common stock will be delivered after the exchange agent has aggregated all fractional shares and sold them in the open market.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated benefits of the exchange offer, Medtronic's and MiniMed's anticipated financial results, all other statements in this communication that are not historical facts, and other risks and uncertainties described in Medtronic's and MiniMed's periodic reports on file with the SEC including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, the Registration Statement on Form S-4 filed by MiniMed in connection with the exchange offer, including the Prospectus forming a part thereof, the Schedule TO, and other exchange offer documents filed by Medtronic or MiniMed, as applicable, with the SEC. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. MiniMed undertakes no obligation to update forward-looking statements or any of the information contained in this press release.

SOURCE MiniMed

Krilogy Financial LLC grew its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 40.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,226 shares of the medical technology company’s stock after purchasing an additional 7,240 shares during the quarter. Krilogy Financial LLC’s holdings in Medtronic were worth $2,319,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Monetary Solutions Ltd bought a new position in Medtronic during the fourth quarter worth about $27,000. IAG Wealth Partners LLC bought a new stake in shares of Medtronic during the 2nd quarter worth approximately $30,000. Pin Oak Investment Advisors Inc. bought a new stake in shares of Medtronic during the 2nd quarter worth approximately $32,000. Global Assets Advisory LLC bought a new stake in shares of Medtronic during the 1st quarter worth approximately $36,000. Finally, Core Capital Management & Research inc. acquired a new stake in shares of Medtronic during the 2nd quarter worth approximately $33,000. 82.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets A number of research analysts recently issued reports on the stock. Bank of America lifted their price objective on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. UBS Group restated a “cautious” rating on shares of Medtronic in a research note on Wednesday. Stifel Nicolaus raised their target price on Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a report on Wednesday, September 2nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a report on Wednesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $102.88.

Check Out Our Latest Report on Medtronic More Medtronic News Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Piper Sandler sees a positive read-through for Medtronic. The analyst commentary suggests recent developments may support the investment case for MDT and likely contributed to buying interest. Piper Sandler on Medtronic: Positive Read-Through for MDT Positive Sentiment: Medtronic reported final results for its MiniMed Group exchange offer. The transaction gives shareholders additional clarity on the separation and ownership structure of the diabetes business. The reported 18.3% proration indicates demand exceeded the shares available for exchange, a potentially favorable sign for investor interest in MiniMed and Medtronic’s strategic repositioning. Medtronic Announces Final Results of MiniMed Group Exchange Offer Neutral Sentiment: Medtronic’s dividend remains attractive to income investors. A comparison with Abbott highlighted MDT’s higher current payout, while Abbott has delivered faster dividend growth. This supports Medtronic’s appeal for yield-focused investors but is more of a long-term valuation consideration than a new earnings catalyst. Medtronic Pays More Today: Abbott Raises Its Dividend Faster Neutral Sentiment: Industry reports project strong growth in mHealth and bioelectronic medicine. Medtronic is listed among major participants in both markets, offering potential long-term opportunities, but the reports do not provide company-specific revenue or earnings changes. mHealth Solutions Market Forecasts Growth Negative Sentiment: Short interest in MDT increased significantly. Rising bearish positioning could create volatility and signals that some investors remain skeptical, despite the recent share-price strength. Medtronic Sees Significant Increase in Short Interest Medtronic Trading Up 1.2% Shares of NYSE MDT opened at $94.14 on Thursday. The firm has a 50 day moving average price of $90.68 and a two-hundred day moving average price of $84.88. The stock has a market cap of $120.41 billion, a P/E ratio of 16.26, a price-to-earnings-growth ratio of 2.12 and a beta of 0.55. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. Medtronic’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Insider Transactions at Medtronic In related news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Medtronic Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Featured Stories Five stocks we like better than Medtronic Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

, /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final results of its previously announced offer to exchange shares of common stock of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) for outstanding Medtronic ordinary shares at an exchange ratio determined by a formula described in a registration statement filed by MiniMed on Form S-4 (Reg No. 333-298914). The exchange offer and withdrawal rights expired at 12:00 midnight, New York City time, at the end of the day on October 9, 2026.

The exchange offer was oversubscribed, and Medtronic has elected to exchange all of its remaining interest in MiniMed (totaling 252,813,348 shares of MiniMed common stock) for 55,032,401 Medtronic ordinary shares.

Because the exchange offer was oversubscribed, Medtronic will accept only a portion of its ordinary shares that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 Medtronic ordinary shares, or an "odd-lot," and have validly tendered all of their shares will not be subject to proration, in accordance with the terms of the exchange offer. All shares validly tendered by eligible "odd-lot" shareholders will be accepted. The final proration factor of 18.289133% will be applied to all other validly tendered Medtronic ordinary shares to determine the number of such shares that will be accepted. Following the completion of the exchange offer, Medtronic will not retain any of the outstanding shares of MiniMed common stock.

Based on the final count by the exchange agent, Equiniti Trust Company, LLC, the final results of the exchange offer are as follows:

Total number of Medtronic ordinary shares validly tendered and not validly withdrawn: 297,521,390 Shares tendered that will be subject to proration: 296,763,500 "Odd-lot" shares tendered that will not be subject to proration: 757,890 Total number of Medtronic ordinary shares that will be accepted: 55,032,401 Medtronic ordinary shares tendered but not accepted for exchange will be returned to the tendering shareholders in book-entry form promptly. In addition, the exchange agent will promptly credit newly issued shares of MiniMed common stock in book-entry form to accounts maintained by the MiniMed transfer agent for tendering shareholders whose Medtronic ordinary shares were accepted in the exchange offer. Checks in lieu of fractional shares of MiniMed common stock will be delivered after the exchange agent has aggregated all fractional shares and sold them in the open market.

Goldman Sachs & Co. LLC and BofA Securities, Inc. served as dealer managers for the exchange offer.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated benefits of the exchange offer, Medtronic's ability to successfully realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders for U.S. federal income tax purposes), MiniMed's ability to succeed as an independent publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in Medtronic's and MiniMed's periodic reports on file with the SEC including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations
+1-763-505-2696

SOURCE Medtronic plc

Medtronic (MDT - Free Report) closed at $93.01 in the latest trading session, marking a +1.17% move from the prior day. This change outpaced the S&P 500's 0.02% loss on the day. Elsewhere, the Dow lost 0.35%, while the tech-heavy Nasdaq lost 0.15%.

Coming into today, shares of the medical device company had lost 1.99% in the past month. In that same time, the Medical sector gained 1.06%, while the S&P 500 gained 2.05%.

The investment community will be paying close attention to the earnings performance of Medtronic in its upcoming release. The company is predicted to post an EPS of $1.34, indicating a 1.47% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $9.47 billion, up 5.66% from the year-ago period.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.98 per share and a revenue of $38.97 billion, signifying shifts of +8.14% and +7.16%, respectively, from the last year.

Investors should also take note of any recent adjustments to analyst estimates for Medtronic. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.17% increase. Medtronic is currently sporting a Zacks Rank of #3 (Hold).

From a valuation perspective, Medtronic is currently exchanging hands at a Forward P/E ratio of 15.38. This denotes a discount relative to the industry average Forward P/E of 19.61.

It is also worth noting that MDT currently has a PEG ratio of 2.09. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.79.

The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 79, placing it within the top 33% of over 250 industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Short sellers are betting heavily against 10 stocks, and the fuse is getting shorter. Each one has more than 38% of its float sold short, with market caps above $2 billion and average daily volume above 1 million shares, according to Benzinga Pro screener data as of Oct. 12.

, /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that, based on preliminary results, its previously announced offer to exchange shares of common stock of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) for outstanding Medtronic ordinary shares was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on October 9, 2026. Medtronic has decided to exchange all of its remaining interest in MiniMed, totaling 252,813,348 shares of MiniMed common stock. Under the terms of the exchange offer, 4.5939 shares of MiniMed common stock will be exchanged for each Medtronic ordinary share accepted in the exchange offer.

According to the exchange agent, Equiniti Trust Company, LLC, 298,024,452 Medtronic ordinary shares were validly tendered and not validly withdrawn, including 93,311,404 shares that were tendered by notice of guaranteed delivery and 757,890 shares that tendered in aggregate by "odd-lot" shareholders (holders of fewer than 100 shares) not subject to proration (including odd-lot shareholders that tendered by notice of guaranteed delivery). Medtronic intends to accept 55,032,401 of the tendered shares in exchange for 252,813,348 shares of MiniMed common stock. Because the exchange offer was oversubscribed, Medtronic is accepting only a portion of its ordinary shares that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned odd-lots and have validly tendered all of their shares will not be subject to proration, in accordance with the terms of the exchange offer.

Based on the total number of Medtronic ordinary shares reported to be tendered prior to the expiration of the exchange offer, it is estimated that approximately 18.3% of the tendered Medtronic ordinary shares will be exchanged, assuming all shares tendered by guaranteed delivery procedures are delivered under the terms of the exchange offer. This preliminary proration factor is subject to change based on the number of tendered shares that satisfy the guaranteed delivery procedures. Medtronic expects to announce the final proration factor on October 14, 2026, promptly following the expiration of the guaranteed delivery period. Medtronic ordinary shares tendered but not accepted for exchange will be returned to the tendering shareholders in book-entry form promptly after the final proration factor is announced. Following the completion of the exchange offer, Medtronic will not retain any of the outstanding shares of MiniMed common stock.

Goldman Sachs & Co. LLC and BofA Securities, Inc. are the dealer managers for the exchange offer.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated timing and benefits of the exchange offer, Medtronic's ability to satisfy the necessary conditions to consummate its separation of MiniMed, Medtronic's ability to successfully consummate the separation of MiniMed and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders for U.S. federal income tax purposes), MiniMed's ability to succeed as an independent publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in Medtronic's and MiniMed's periodic reports on file with the SEC including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

Additional Information and Where to Find It
This communication is for informational purposes only and is not an offer to sell or exchange, a solicitation of an offer to buy or exchange any securities or a recommendation as to whether investors should participate in the exchange offer. There shall be no solicitation, offer, sale or exchange of any securities in any jurisdiction in which such solicitation, offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. MiniMed has filed with the SEC a registration statement on Form S-4 (the "Registration Statement") that includes a Prospectus. The exchange offer is made solely by the Prospectus. The Prospectus contains important information about the exchange offer, Medtronic, MiniMed and related matters, and Medtronic has delivered the Prospectus to holders of Medtronic ordinary shares.  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE MAKING ANY INVESTMENT DECISION, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. None of Medtronic, MiniMed or any of their respective directors or officers or the dealer managers appointed with respect to the exchange offer makes any recommendation as to whether you should participate in the exchange offer.

Medtronic has filed with the SEC a Schedule TO, which contains important information about the exchange offer.

Holders of Medtronic ordinary shares may obtain copies of the Prospectus, the Registration Statement, the Schedule TO and other related documents, and any other information that Medtronic and MiniMed file electronically with the SEC free of charge at the SEC's website at http://www.sec.gov. Holders of Medtronic ordinary shares may also obtain a copy of the Prospectus by clicking on the appropriate link at http://www.dfking.com/MDTSeparation.

Medtronic has retained D.F. King & Co., Inc. as the information agent for the exchange offer. To obtain copies of the exchange offer Prospectus and related documents, or for questions about the terms of the exchange offer or how to participate, you may contact the information agent at +1 (877) 361-7972 (toll-free for shareholders) or +1 (646) 845-0146 (banks, brokers, and all others outside the United States).

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations 
+1-763-505-2696

SOURCE Medtronic plc

, /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinary shares for shares of common stock of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). Medtronic is offering to exchange up to 225,361,295 shares of MiniMed common stock for outstanding Medtronic ordinary shares in the exchange offer and, if the exchange offer is oversubscribed, Medtronic currently intends to exchange all of Medtronic's remaining interest in MiniMed (an additional 27,452,053 shares of MiniMed common stock), without extending the exchange offer period.

For each Medtronic ordinary share that is validly tendered and not validly withdrawn by shareholders and that is accepted by Medtronic pursuant to the exchange offer, Medtronic will deliver 4.5939 shares of MiniMed common stock to or at the direction of any such tendering shareholder.

The final calculated per-share value of Medtronic ordinary shares and the final calculated per-share value of MiniMed common stock, in each case determined in the manner described in the Prospectus filed by MiniMed with the U.S. Securities and Exchange Commission (the "SEC"), would have resulted in an exchange ratio of more than the upper limit of 4.5939. Accordingly, the final exchange ratio has been set at 4.5939 shares of MiniMed common stock for each Medtronic ordinary share accepted in the exchange offer.

Based on the final exchange ratio, assuming the exchange offer is oversubscribed, Medtronic would accept for exchange approximately 55,032,401 Medtronic ordinary shares if Medtronic decides to exchange all of its remaining interest in MiniMed, or approximately 49,056,639 Medtronic ordinary shares if Medtronic does not increase the number of shares to be accepted, as described in the Prospectus. Because the exchange offer will be subject to proration if the exchange offer is oversubscribed, the number of Medtronic ordinary shares that Medtronic accepts in the exchange offer may be less than the number of shares validly tendered by Medtronic shareholders.

The exchange offer and withdrawal rights will expire at 12:00 midnight, New York City time, at the end of the day on October 9, 2026, unless the exchange offer is extended or terminated.

Goldman Sachs & Co. LLC and BofA Securities, Inc. are the dealer managers for the exchange offer.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated timing and benefits of the exchange offer, Medtronic's ability to satisfy the necessary conditions to consummate its separation of MiniMed, Medtronic's ability to successfully consummate the separation of MiniMed and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders for U.S. federal income tax purposes), MiniMed's ability to succeed as an independent publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in Medtronic's and MiniMed's periodic reports on file with the SEC including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

Additional Information and Where to Find It
This communication is for informational purposes only and is not an offer to sell or exchange, a solicitation of an offer to buy or exchange any securities or a recommendation as to whether investors should participate in the exchange offer. There shall be no solicitation, offer, sale or exchange of any securities in any jurisdiction in which such solicitation, offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. MiniMed has filed with the SEC a registration statement on Form S-4 (the "Registration Statement") that includes a Prospectus. The exchange offer is made solely by the Prospectus. The Prospectus contains important information about the exchange offer, Medtronic, MiniMed and related matters, and Medtronic has delivered the Prospectus to holders of Medtronic ordinary shares. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE MAKING ANY INVESTMENT DECISION, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. None of Medtronic, MiniMed or any of their respective directors or officers or the dealer managers appointed with respect to the exchange offer makes any recommendation as to whether you should participate in the exchange offer.

Medtronic has filed with the SEC a Schedule TO, which contains important information about the exchange offer.

Holders of Medtronic ordinary shares may obtain copies of the Prospectus, the Registration Statement, the Schedule TO and other related documents, and any other information that Medtronic and MiniMed file electronically with the SEC free of charge at the SEC's website at http://www.sec.gov. Holders of Medtronic ordinary shares may also obtain a copy of the Prospectus by clicking on the appropriate link at http://www.dfking.com/MDTSeparation.

Medtronic has retained D.F. King & Co., Inc. as the information agent for the exchange offer. To obtain copies of the exchange offer Prospectus and related documents, or for questions about the terms of the exchange offer or how to participate, you may contact the information agent at +1 (877) 361-7972 (toll-free for shareholders) or +1 (646) 845-0146 (banks, brokers, and all others outside the United States).

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations 
+1-763-505-2696

SOURCE Medtronic plc

Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising choice.

It might seem like a risky time to buy new stocks. The Fed raised its benchmark rates for the first time in three years in September, and the 10-Year Treasury's 5.3% yield -- its highest level since 2007 -- is pulling investors toward safer fixed-income investments.

But over the long run, many blue chip dividend stocks still outperform CDs, bonds, and T-bills. Let's take a look at two of those stocks -- AbbVie (ABBV +1.12%) and Medtronic (MDT +1.84%) -- which are worth buying with $5,000 (or more) to ride out the near-term volatility.

Image source: Getty Images.

AbbVie AbbVie, one of the world's largest pharmaceutical companies, has raised its dividend annually for 53 consecutive years. That makes it a Dividend King, a company that has increased its payout for at least 50 straight years. It pays a forward yield of 2.6%.

In 2023, AbbVie lost its U.S. patent exclusivity for Humira, its blockbuster autoimmune drug. But to offset that blow, it acquired several companies -- including Allergan (the maker of Botox), ImmunoGen, and Cervel -- and launched new blockbuster drugs like Skyrizi and Rinvoq.

Premium Feature

Moneyball Superscore

80/100

Today's Change

(

1.12

%) $

2.94

Current Price

$

265.76

That aggressive expansion paid off, and analysts expect its revenue and adjusted EPS to grow at CAGRs of 9% and 21%, respectively, from 2025 to 2028. That growth should be driven by Skyrizi and Rinvoq, ImmunoGen's oncology drugs, and Cervel's neuroscience drugs.

Its stock has risen 15% year to date and is hovering near its record high, but it still looks like a bargain at 16 times next year's earnings. It's not an exciting investment, but it's a safe place to park your cash and earn some passive income.

Medtronic Medtronic, one of the world's top medical device makers, is on the verge of becoming a Dividend King with 49 consecutive years of dividend hikes. It pays a forward yield of 3.3%.

Over the past few years, Medtronic struggled with supply chain constraints, rising costs, quality control issues, and tougher competition. But to stabilize its business, Medtronic spun off its diabetes unit as MiniMed (MMED +2.33%), reined in its spending, and focused on expanding its higher-growth cardiovascular and neuroscience businesses.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

1.84

%) $

1.59

Current Price

$

87.97

Those turnaround efforts boosted Medtronic's organic revenue by 5.8% in fiscal 2026 (which ended this April), and it expects that figure to rise another 7.25%-7.75% in fiscal 2027.

From fiscal 2026 to fiscal 2029, analysts expect its reported revenue and EPS to grow at CAGRs of 5% and 15%, respectively. Yet its stock is still down 8% year-to-date and trades at just 18 times this year's earnings -- so it could be another reliable stock to buy and hold in this shaky market.

Argent Capital Management LLC lowered its position in Medtronic PLC (NYSE:MDT – Free Report) by 4.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 174,092 shares of the medical technology company’s stock after selling 7,596 shares during the quarter. Argent Capital Management LLC’s holdings in Medtronic were worth $15,022,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. grew its holdings in Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after buying an additional 838,220 shares in the last quarter. State Street Corp raised its stake in Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after acquiring an additional 1,658,301 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Medtronic by 2.7% during the 4th quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after acquiring an additional 1,419,730 shares during the period. Capital Research Global Investors boosted its position in Medtronic by 12.6% during the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after acquiring an additional 3,880,174 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after purchasing an additional 1,343,220 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic In other news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes A number of equities research analysts recently weighed in on MDT shares. Wells Fargo & Company lifted their price objective on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a research report on Wednesday, September 2nd. Weiss Ratings raised shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, BTIG Research increased their price objective on shares of Medtronic from $91.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 1st. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $103.92. Read Our Latest Research Report on MDT

Medtronic Price Performance Shares of NYSE MDT traded up $1.40 during midday trading on Monday, reaching $87.78. The company’s stock had a trading volume of 15,391,785 shares, compared to its average volume of 9,446,150. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average price of $90.15 and a 200 day moving average price of $84.76. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The company has a market cap of $112.28 billion, a price-to-earnings ratio of 21.63, a price-to-earnings-growth ratio of 1.97 and a beta of 0.55.

Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business’s quarterly revenue was up 13.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is 70.94%.

Medtronic Company Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Featured Articles Five stocks we like better than Medtronic What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Insiders Are Selling These 3 Stocks, Should You? Datadog’s Rally Has Insiders Selling—Can It Keep Climbing?

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

MassMutual Private Wealth & Trust FSB increased its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 14.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 149,708 shares of the medical technology company’s stock after buying an additional 19,315 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Medtronic were worth $12,918,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after purchasing an additional 838,220 shares in the last quarter. State Street Corp raised its stake in Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after buying an additional 1,658,301 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Medtronic by 2.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock valued at $5,150,420,000 after buying an additional 1,419,730 shares in the last quarter. Capital Research Global Investors lifted its holdings in Medtronic by 12.6% during the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after buying an additional 3,880,174 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after buying an additional 1,343,220 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Down 0.1% Shares of Medtronic stock opened at $86.31 on Monday. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The stock has a market cap of $110.40 billion, a PE ratio of 21.26, a price-to-earnings-growth ratio of 1.97 and a beta of 0.55. The company has a 50-day moving average of $90.15 and a two-hundred day moving average of $84.76.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the company earned $1.26 EPS. The company’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year. Medtronic Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Buying and Selling In other Medtronic news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades A number of research analysts have recently commented on MDT shares. Weiss Ratings upgraded Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, September 4th. Bank of America boosted their target price on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Evercore set a $105.00 price target on Medtronic in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $92.00 price target on shares of Medtronic in a research note on Thursday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Nineteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $103.92.

Get Our Latest Stock Analysis on Medtronic

More Medtronic News Here are the key news stories impacting Medtronic this week:

Positive Sentiment: TD Cowen reiterated a “Buy” rating on Medtronic, providing an analyst-confidence signal for the medical-device maker. Medtronic Earns Buy Rating from TD Cowen Positive Sentiment: The FDA granted breakthrough-device designation to Medtronic’s below-the-knee drug-coated balloon, potentially accelerating regulatory interaction and supporting the company’s peripheral vascular pipeline. Medtronic Receives Breakthrough Designation Positive Sentiment: The American Medical Association approved Category I CPT codes for the Altaviva tibial neuromodulation device and Symplicity Spyral renal-denervation system. The codes become effective in January 2028 and could improve reimbursement visibility and adoption over the long term. Medtronic CPT Code Approvals Positive Sentiment: New regulatory clearances for cardiac mapping and ablation software may strengthen Medtronic’s competitive position in the growing pulsed-field ablation market. Medtronic Cardiac Software Clearances Neutral Sentiment: A commentary argues that Medtronic’s dividend and defensive healthcare exposure could remain attractive if inflation and interest rates stay elevated, but it does not represent a new company-specific catalyst. Inflation and Dividend Stocks Neutral Sentiment: An investment opinion says Medtronic’s long-term strategy could still appeal to investors, although Johnson & Johnson’s stronger historical performance highlights execution concerns. Johnson and Johnson Compared With Medtronic Negative Sentiment: The $4 billion tax-free MiniMed exchange offer appears to be losing investor appeal. Reduced participation could make the split-off a weaker near-term catalyst and leave shareholders focused on execution and valuation risks. Medtronic MiniMed Exchange Offer Negative Sentiment: Medtronic’s stock has declined since its latest earnings report, with investors apparently looking for stronger forward earnings momentum despite the prior quarterly revenue and EPS beat. Medtronic Stock Since Earnings Negative Sentiment: Put-option volume was about 45% above average, indicating increased downside hedging or bearish positioning around MDT. Medtronic Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Featured Articles Five stocks we like better than Medtronic Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam? The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning? Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why investors should own it.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Shares of Medtronic (NYSE:MDT | MDT Price Prediction) trade at $86.75. They are down 7.4% this year and 20.06% over five years, and the dividend kept going up the whole time. Now the business is growing faster than it has in years. That makes it fair to ask whether the payout is still the main reason to own the stock.

Repeat Procedure Revenue Pays for the Dividend Medtronic makes the equipment doctors use in the operating room and the cath lab: pacemakers, heart ablation catheters, spine and brain surgery tools, surgical robots and insulin pumps. A lot of that revenue comes back every year. Each ablation procedure uses a new catheter, and each mapping system a hospital sets up leads to more catheter orders. On the latest earnings call, management said the growing sets up base should drive future sales of higher-margin catheters.

That repeat business has funded a 49th consecutive year of dividend increases. The quarterly payout has grown from $0.04 in 2000 to $0.72, or $2.88 a year, for a yield of about 3.27%. Coverage is solid. Fiscal 2026 dividends of $3.639 billion used about 67% of $5.43 billion in free cash flow. The forward payout is about 48% of the $5.972 consensus EPS for fiscal 2027. The weak spot is how fast it grows: the latest raise from $0.71 works out to about 1.4%.

A 49-year streak puts Medtronic one raise away from Dividend King status, the 50-plus-year club we rated by valuation in a free report here: 10 Dividend Kings to Buy Now and Hold Forever.

Growth Now Comes From the Heart Business Revenue for the first quarter of fiscal 2027 came in at $9.76 billion, up 13.7%. Non-GAAP EPS of $1.45 beat the $1.39 estimate. An extra fiscal week added about $570 million, or 670 basis points, to that growth. Even without it, ablation stood out. Cardiac Ablation Solutions grew 88% worldwide and 139% in the U.S., and the Sphere-9 catheter picked up nine points of U.S. share.

“Our execution, alongside our innovation engine, positions us to serve more patients and deliver durable growth,” CEO Geoff Martha said.

Other areas lag. Neuromodulation grew just 3%, and management guided second-quarter organic growth to roughly 6%.

How Abbott and Boston Scientific Frame the Choice Abbott Laboratories (NYSE:ABT) has the longer record, with a 54th consecutive year of increases and a $0.63 quarterly payout. Its second-quarter revenue rose 13.0%, but only 4.8% on a comparable basis once Exact Sciences is included.

Boston Scientific (NYSE:BSX) pays no dividend and wants investors to pay up for FARAPULSE growth. Its 2026 organic outlook fell from 10.0% to 11.0% to 5% to 6%. A widely upvoted Reddit post summed it up:

“Boston Scientific peaked at $105 last November. It closed yesterday at $43.55.”

Valuation Gives Medtronic Little Credit for Growth Medtronic trades at 15 times forward earnings and 21 times trailing earnings. Analysts rate it 3 Strong Buy, 16 Buy and 9 Hold. Their $104.83 average target means about 20.8% upside.

Verdict: The Dividend Is the Floor, Ablation Is the Reason The dividend now plays a supporting role. It puts a floor under the stock, while ablation, renal denervation and the Diabetes spinoff provide the upside. Management expects the spinoff to lift operating margin by about 100 basis points. The biggest risk is ablation growth slowing toward the mid-teens market rate as year-over-year comparisons get harder. If that happens, Medtronic goes back to being a slow-growth income stock. The investor day on December 10th and 11th is the next checkpoint.

Contact [email protected] for any questions or corrections.

After 100 days at the head of the Federal Reserve, Kevin Warsh gave a speech outlining the economic situation. While employment has been stable, which is positive, Warsh was clearly more concerned about inflation: "Inflation is running above our 2 percent target. So the Fed's predominant focus right now should be on prices."

He went on to note that, "Price stability is not self-executing, nor is inflation necessarily mean-reverting. It is the Fed's job to deliver stable prices." The key Fed tool for dealing with inflation is adjusting interest rates, which is a blunt instrument, at best. With one rate increase already in the books, it seems likely that more are on the way. Which is why investors may want to consider high-yield healthcare stocks like Medtronic (MDT +0.17%) and Pfizer (PFE -1.40%). Here's a look at each one.

Image source: The Federal Reserve.

Healthcare isn't an option When inflation is running hot, meaning costs are rising, consumers attempt to tighten their budgets. That is less of an issue in the healthcare sector because people are dealing with quality-of-life issues and, sometimes, even life or death issues. Essentially, spending on healthcare is far less optional than whether you buy a brand-name soda or the store-brand version.

That's not to suggest that healthcare stocks are immune to headwinds. In fact, the reason Medtronic and Pfizer have well-above-market yields of 3.2% and 6%, respectively, is that they are dealing with company-specific problems. However, that's actually what creates the value opportunity here for income lovers with long investment time horizons.

Premium Feature

Moneyball Superscore

74/100

Today's Change

(

0.17

%) $

0.15

Current Price

$

86.44

Medtronic is turning back to growth Medtronic is a large and diversified medical device maker. Over the years, its business grew bloated, and growth slowed. Investors dumped the stock, even though management acknowledged the problem and was working to address it. Non-core assets were sold as the company worked to streamline and refocus on its most profitable and fasted growing divisions.

It was a fairly long process, and investors have taken a show-me stance. But the company is executing well on the turnaround, with fiscal 2026 producing the highest annual revenue growth in 10 years. The fiscal first quarter of 2027 continued the good news, with 13.7% revenue growth. But for dividend investors, the biggest positive is that Medtronic has increased its dividend for 49 consecutive years, just one year shy of Dividend King status. This is a reliable dividend stock with an attractive yield and a business that is starting to show signs of renewed strength.

Premium Feature

Moneyball Superscore

64/100

Today's Change

(

-1.40

%) $

-0.40

Current Price

$

28.12

Pfizer has more work to do Pfizer is a large and well-respected pharmaceutical company. It is dealing with fairly typical headwinds in the sector, as it has drugs losing patent protection but few new drugs to offset the resulting revenue hit. It is a timing mismatch: patent expirations follow a schedule, but drug discovery and development do not. Investors are worried that the company won't be able to support its dividend through this difficult period.

That's not unreasonable; however, the company has stated explicitly that it intends to support the dividend. And it has a large cash hoard (roughly $11 billion at the end of the second quarter of 2026) to help bridge the gap. Given the company's long and successful history of developing new drugs, the lofty yield seems worth the risk for more aggressive income investors.

People are likely to keep paying to live better lives To bring the story back to the core theme, Kevin Warsh is clearly telling investors that costs are rising, and that isn't a good thing. However, all expenses are not viewed the same way. Some are optional, others are not. Healthcare generally falls into the not optional camp. For dividend investors, that should make high-yield Medtronic, which appears to have turned around its business, and Pfizer, which is still working to deal with drug expirations, attractive right now.

It has been about a month since the last earnings report for Medtronic (MDT - Free Report) . Shares have lost about 6.4% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Medtronic due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Medtronic PLC before we dive into how investors and analysts have reacted as of late.

Medtronic's Q1 Earnings & Revenues Top EstimatesMedtronic plc reported first-quarter fiscal 2027 adjusted earnings per share of $1.45 per share, which rose 15.1% year over year and topped the Zacks Consensus Estimate by 4.3%.

The metric excludes certain one-time adjustments, including amortization of intangible assets, restructuring and associated costs, as well as acquisition and divestiture-related items.

On a GAAP basis, earnings per share came in at $1.14, up from 81 cents a year earlier.  

Revenues rose 13.7% year over year to $9.76 billion and beat the consensus mark by 3%. The quarter included an extra fiscal week, which benefited organic growth by approximately $570 million.

MDT’s Segmental Performance Remains Broad-Based

Cardiovascular revenues totaled $3.93 billion in the first quarter of fiscal 2027, up 19.5% year over year on a reported basis and 18.9% organically. Within this, Electrophysiology Therapies revenues rose 29.1%, while Interventional Cardiology Therapies revenues were up 6.5% organically. CardioVascular Surgery and Peripheral Vascular Health revenues advanced 8.1% and 11% respectively, on an organic basis.  

Neuroscience revenues came in at $2.68 billion, up 10.3% reported and 9.3% organically. Cranial & Spinal Technologies led the portfolio with 12.9% organic growth. Specialty Therapies revenues increased 7.4% organically, while Neuromodulation posted 3.3% organic growth.

Medical Surgical revenues were $2.28 billion, up 10% year over year and 10.2% organically. Surgical & Endoscopy revenues increased 9% organically, while Acute Care & Monitoring revenues rose 14.2% organically.

Diabetes revenues jumped 16.9% to $843 million, with organic growth of 14.9%.

MDT Delivers Strong U.S. and Overseas Growth

U.S. revenues rose 16.1% to $4.91 billion, with organic growth of 15.8%. U.S. Cardiovascular was particularly strong, increasing 25.3%, as Electrophysiology Therapies revenues climbed 41.2%.

International revenues advanced 11.4% to $4.85 billion and grew 11.6% organically. International Diabetes recorded 16.8% organic growth, while Cardiovascular increased 13.7%, highlighting strength across major overseas businesses.

MDT’s Q1 Margin Performance

The gross margin in the reported quarter remained flat year over year at 65% despite a 13.8% increase in the cost of products sold, excluding amortization of intangible assets, to $3.42 billion.

Research and development expenses rose 6.2% year over year to $771 million. Selling, general and administrative expenses increased 14% to $3.20 billion.

The adjusted operating margin expanded 10 basis points year over year to 23.7%.

Medtronic Raises Fiscal 2027 Guidance

Medtronic raised its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from the prior 6.75%-7.25% range.

The company also lifted adjusted EPS guidance to $5.94-$6.00 from the prior $5.90-$6.00 outlook. The guidance incorporates an estimated neutral to 1% accretive foreign currency impact based on recent exchange rates. Medtronic also highlighted recent acquisitions of Scientia Vascular and SPR Therapeutics and continued investment in growth platforms.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.

VGM ScoresCurrently, Medtronic has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. Charting a somewhat similar path, the stock has a score of B on the value side, putting it in the top 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Medtronic has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerMedtronic is part of the Zacks Medical - Products industry. Over the past month, Agilent Technologies (A - Free Report) , a stock from the same industry, has gained 13.8%. The company reported its results for the quarter ended July 2026 more than a month ago.

Agilent reported revenues of $1.88 billion in the last reported quarter, representing a year-over-year change of +8.1%. EPS of $1.62 for the same period compares with $1.37 a year ago.

Agilent is expected to post earnings of $1.72 per share for the current quarter, representing a year-over-year change of +8.2%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Agilent. Also, the stock has a VGM Score of F.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Medtronic (MDT - Free Report) Medtronic plc was formed after Medtronic, Inc., the legacy NYSE-listed parent company incorporated in Minnesota, acquired Ireland-based Covidien plc for cash and stock of $49.9 billion in 2015. The transaction created a new holding company incorporated in Ireland, which became the NYSE-listed parent company for both legacy businesses.

MDT is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.56; value investors should take notice.

10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2027, while the Zacks Consensus Estimate has increased $0.04 to $5.98 per share. MDT also boasts an average earnings surprise of +2.8%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, MDT should be on investors' short list.

Medtronic (MDT - Free Report) closed at $87.09 in the latest trading session, marking a -2.69% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.17%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 0.09%.

Prior to today's trading, shares of the medical device company had lost 1.27% lagged the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.

The investment community will be closely monitoring the performance of Medtronic in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $1.34, reflecting a 1.47% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $9.47 billion, indicating a 5.63% upward movement from the same quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.98 per share and a revenue of $38.96 billion, representing changes of +8.14% and +7.14%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.61% higher. As of now, Medtronic holds a Zacks Rank of #3 (Hold).

Digging into valuation, Medtronic currently has a Forward P/E ratio of 14.97. This represents a discount compared to its industry average Forward P/E of 20.02.

Investors should also note that MDT has a PEG ratio of 2.04 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Products industry stood at 1.75 at the close of the market yesterday.

The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 107, placing it within the top 44% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

People keep needing pacemakers, glucose monitors, and syringes whether the economy is expanding or shrinking. That steady demand lets the best medical device makers raise their dividends through every kind of market. Abbott Laboratories (NYSE:ABT | ABT Price Prediction), Medtronic (NYSE:MDT), and Becton Dickinson (NYSE:BDX) have each pushed their quarterly payout higher within the past year. The group’s anchor is Abbott, which is now in its 54th consecutive year of dividend increases. These are modest yields with a reliable growth engine behind them, and for a retiree that engine matters more than the starting number.

Abbott Laboratories: Biggest Raise of the Group Abbott pays $0.63 per share each quarter, up from $0.59 before its most recent raise. That is the largest increase of the three names here, and it sets the forward annual rate at $2.52 per share. With shares at $100.98, the stock yields 2.45%, which puts it in dividend-growth territory rather than high-yield territory.

Dividend Safety Read A quick definition for newer income investors: free cash flow is the cash left after a company funds its operations and capital spending, and it is the pool dividends actually come from. For 2025, Abbott generated $9.566 billion in operating cash flow against $2.171 billion in capital expenditures, while paying $4.116 billion in dividends. The latest quarter looked similar: $2.488 billion of operating cash flow, $399 million of capex, and $1.102 billion in dividends.

On earnings, trailing GAAP EPS of $3.09 sits above the $2.48 in dividends paid per share over the same stretch. GAAP profit is reduced by $658 million of amortization tied to the Exact Sciences deal. Management’s raised 2026 adjusted EPS guidance of $5.45 to $5.60 gives the $2.52 forward dividend a much wider buffer. Abbott’s dividend history stands out: the most recent payment was the 410th consecutive quarterly dividend, and Abbott is a member of the S&P 500 Dividend Aristocrats Index. Total dividend outlays rose every year from $3.202 billion in 2021 to $4.116 billion in 2025.

Fifty straight years of raises puts Abbott in rare company, and we ranked ten of those Dividend Kings by valuation in a free report you can grab here.

Bull Case for Income Investors Abbott’s payout is funded by four engines: medical devices, diagnostics, nutrition, and branded generic medicines. When one segment stalls, the others carry the load. Second-quarter revenue reached $12.59 billion, up 13.0% year over year, and adjusted EPS of $1.31 beat the $1.28 estimate. The stock is down 17.91% year to date and trades at about 17x forward earnings, so new buyers lock in the yield at a lower entry price. Analysts are positive, with 4 strong buy ratings, 17 buys, and zero sells, plus a consensus target of $120.26.

Risk to Watch The Exact Sciences acquisition added debt. Quarterly interest expense rose to $299 million from $50 million, a new fixed cost that competes with dividend growth until the deal pays for itself.

Medtronic: Highest Yield and a 49-Year Raise Streak Medtronic lifted its quarterly dividend to $0.72 from $0.71, a one-cent bump that marked its 49th consecutive year of dividend increases. The forward annual rate is $2.88 per share. At $88.30 a share, the yield is 3.22%, the highest of this trio.

Dividend Safety Read Cash coverage improved significantly last quarter. Free cash flow reached $1.29 billion, up 120.9%, against $921 million in dividends paid. For the full fiscal year ended in April, operating cash flow of $7.33 billion and capex of $1.904 billion compared with $3.639 billion in dividends. Trailing EPS of $4.06 covers the $2.88 forward payout, and raised fiscal 2027 non-GAAP EPS guidance of $5.94 to $6.00 widens that margin further. Management also found room for $1.035 billion of buybacks in fiscal 2026.

Bull Case for Income Investors Growth is back. First-quarter revenue rose 13.7% to $9.76 billion, helped by an extra fiscal week worth roughly $570 million. Cardiac Ablation Solutions grew 88%, and CEO Geoff Martha pointed to the strongest annual top-line growth in 10 years. Adjusted EPS of $1.45 beat the $1.39 estimate. The stock trades near 15x forward earnings with a beta of 0.574, so retirees get a higher starting yield with below-market volatility.

Risk to Watch Medtronic plans to separate its Diabetes business. Breakups bring one-time costs, stranded overhead, and a smaller earnings base, and the board will need to prove the remaining company can keep the streak moving toward 50 years without strain.

Becton Dickinson: A Leaner Company Still Raising BD pays $1.05 per quarter, up from $1.04, for a forward annual rate of $4.20. At $183.83 a share, the yield is 2.28%. BD has the newest story of the three: it spun off its Biosciences and Diagnostic Solutions business in February 2026 and now runs as a pure-play medtech company.

Can a Slimmer BD Carry This Payout? Yes, based on the cash numbers. Year-to-date free cash flow reached $1.73 billion, up 44.6%, while dividends over the same period totaled $0.9 billion. BD also funded roughly $2.3 billion in buybacks, which signals management sees excess capacity. Raised fiscal 2026 adjusted EPS guidance of $12.62 to $12.72 exceeds the $4.20 forward dividend. Trailing GAAP EPS is a lower $5.77, weighed down by $487 million in restructuring charges and a $450 million non-cash impairment. Net leverage sits near 2.9 times, above the 2.5 times long-term target. The dividend record shows an increase every year in the available history, climbing from $0.495 in 2013 to today’s rate.

Bull Case for Income Investors The new BD is posting clean results. Third-quarter adjusted EPS of $3.23 beat the $3.14 estimate, and revenue of $4.98 billion exceeded the $4.89 billion forecast. BD has signed approximately 100 agreements across GLP-1 drug programs, and PureWIC has logged 37 consecutive quarters of double-digit growth. CEO Tom Polen summed up the restructuring: “This is our first quarter as a focused med tech company.” Investors have noticed. Shares are up 22.81% year to date, the stock outperformed competitors on a strong trading day last week, and it still trades around 14x forward earnings.

Risk to Watch Fiscal 2027 carries a known drag as Alaris remediation winds down. CFO Vitor Roque said, “We have consistently characterized FY27 as low single-digit revenue growth, and that is due to the Alaris remediation coming to an end in FY26, which creates a 200 basis points headwind.” Slower top-line growth could keep future raises small.

Why These Three Raisers Belong in a Retirement Portfolio Abbott, Medtronic, and BD all yield between roughly 2% and 3.5%, and each backs its payout with free cash flow that well exceeds what it sends to shareholders. For a retiree, a dividend that climbs every year protects purchasing power in a way a static high yield cannot. Abbott brings the biggest raise and a 54-year streak, Medtronic brings the highest yield and 49 straight increases, and BD brings a newly focused business with fast-growing cash flow. Together they turn steady medical demand into a rising income stream.

Contact [email protected] for any questions or corrections.

Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 17.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 73,993 shares of the medical technology company’s stock after purchasing an additional 10,960 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Medtronic were worth $5,788,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ipsen Advisor Group LLC grew its holdings in Medtronic by 1.7% in the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after buying an additional 101 shares during the period. Arlington Trust Co LLC raised its stake in Medtronic by 11.6% during the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after purchasing an additional 120 shares during the period. Bigelow Investment Advisors LLC raised its stake in Medtronic by 1.1% during the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock worth $964,000 after purchasing an additional 121 shares during the period. Bank & Trust Co raised its stake in Medtronic by 2.8% during the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock worth $342,000 after purchasing an additional 121 shares during the period. Finally, Integrity Alliance LLC. boosted its holdings in shares of Medtronic by 1.7% in the 2nd quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock valued at $578,000 after purchasing an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic News Summary Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Robotics partnership expands growth opportunity: Medtronic’s $700 million strategic partnership with Cornerstone Robotics gives it rights to distribute the Sentire surgical system in select markets outside the U.S. Medtronic plans to offer Sentire alongside its Hugo robotic-assisted surgery platform in Europe, China and Singapore, potentially broadening its presence in the rapidly expanding surgical-robotics market. Could Medtronic’s $700 Million Robotics Bet Unlock Its Next Growth Engine? Positive Sentiment: Favorable industry trends support long-term growth: The global medical-robots market is forecast to roughly double from $20.6 billion in 2026 to $41.7 billion by 2031. Medtronic is positioned to benefit from increasing demand for minimally invasive procedures and hospital automation. Medical Robots Market Forecasts Growth Positive Sentiment: Analyst remains bullish: A recent research note initiated Medtronic with a Buy rating and a $106.33 price target, citing a roughly 3% dividend yield, strong free-cash-flow growth and strength in the Cardiovascular and Neuroscience businesses. Medtronic: Buy the 3% Yield and Strong Free Cash Flow Growth Neutral Sentiment: Wall Street remains divided: Analysts raised price targets following Medtronic’s fiscal 2027 first-quarter earnings beat, but disagreement persists over whether accelerating revenue growth can justify a higher valuation multiple. Medtronic Q1 Beat Sparks Target Hikes Negative Sentiment: Near-term margin concerns may limit enthusiasm: Although revenue and EPS guidance improved, margin expansion is expected to develop gradually as Medtronic shifts toward higher-margin recurring revenue, tempering the potential for an immediate re-rating. Insider Activity In other news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.27% of the company’s stock. Analysts Set New Price Targets MDT has been the subject of several research reports. Mizuho set a $115.00 price objective on shares of Medtronic in a research note on Wednesday, September 2nd. Wells Fargo & Company increased their target price on Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 2nd. Bank of America lifted their target price on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. Weiss Ratings raised Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, September 4th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $92.00 price target on shares of Medtronic in a research note on Thursday, September 3rd. Nineteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $103.92.

Read Our Latest Stock Report on Medtronic

Medtronic Stock Down 0.9% Shares of Medtronic stock opened at $88.49 on Friday. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The stock has a market cap of $113.19 billion, a price-to-earnings ratio of 21.79, a price-to-earnings-growth ratio of 2.07 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average price of $89.58 and a 200 day moving average price of $84.82.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is 70.94%.

Medtronic Company Profile (Free Report)

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.

Read More Five stocks we like better than Medtronic Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Paychex Plunges, Providing the Entry Investors Have Been Waiting For The Case for Buying High-Yield General Mills Just Strengthened SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

24.77K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.